instead
anticip
influenza
pandem
viral
antigen
shift
surfac
hemagglutinin
subtyp
season
either
swine
origin
influenza
viru
replac
season
caus
present
pandem
although
antigen
chang
expect
associ
clinic
sever
due
gener
lack
neutral
antibodi
crude
mortal
rate
develop
countri
compar
season
influenza
despit
major
death
associ
major
underli
ill
higher
rate
sever
diseas
younger
age
sector
merit
investig
moreov
new
viru
appear
recent
jump
swine
human
replic
effici
lower
respiratori
tract
laboratori
mammal
compar
recent
season
influenza
virus
although
smoke
pregnanc
morbid
obes
highlight
import
risk
factor
complic
sever
case
pathogenesi
investig
serial
viral
load
immunolog
studi
case
fatal
influenza
infect
persist
high
viral
load
mark
proinflammatori
cytokin
activ
initi
contain
phase
pandem
influenza
epidem
hong
kong
known
infect
patient
compulsorili
isol
hospit
provid
opportun
take
serial
clinic
sampl
compar
clinic
progress
viral
load
cytokin
chemokin
level
histopatholog
find
laboratoryconfirm
case
differ
clinic
sever
implic
pathogenesi
treatment
discuss
seventyfour
patient
admit
hospit
hong
kong
may
septemb
test
posit
pandem
influenza
viru
includ
studi
twentythre
patient
either
develop
acut
respiratori
distress
syndrom
ard
andor
die
ardsdeath
group
group
patient
die
develop
ard
anoth
group
patient
develop
oxygen
desatur
breath
room
air
requir
respiratori
support
surviv
without
develop
ard
survivedwithoutard
group
thirtyseven
patient
isol
hospit
period
without
respiratori
decompens
randomli
select
repres
milddiseas
group
method
studi
approv
institut
review
board
hospit
author
hong
kong
clinic
find
includ
histori
physic
examin
oximetr
measur
hematolog
biochem
radiolog
microbiolog
investig
result
enter
predesign
databas
acut
physiolog
chronic
health
evalu
ii
score
record
ard
multiorgan
dysfunct
syndrom
defin
standard
criteria
observ
group
death
discharg
hospit
patient
diagnosi
pandem
influenza
viru
infect
confirm
either
pandem
gene
test
posit
reversetranscript
polymeras
chain
reaction
rtpcr
viral
cultur
nasopharyng
endotrach
specimen
laboratori
procedur
perform
previous
report
serial
nasopharyng
intub
endotrach
viral
load
assess
quantit
pcr
influenza
viru
gene
detect
limit
assay
copi
rnaml
blood
urin
fecal
sampl
also
test
oseltamivir
resist
directli
detect
initi
posit
nasopharyng
endotrach
sampl
rtpcr
sequenc
fragment
neuraminidas
gene
span
posit
crt
mutat
test
repeat
respiratori
specimen
patient
persist
high
viral
load
despit
oseltamivir
treatment
initi
respiratori
tract
sampl
cultur
madin
darbi
canin
kidney
cell
line
trypsin
day
respiratori
tract
sampl
admiss
also
assess
multiplex
pcr
luminex
resplex
ii
assay
qiagen
coinfect
respiratori
syncyti
viru
influenza
b
viru
parainfluenza
virus
human
metapneumoviru
enterovirus
rhinoviru
adenoviru
bocaviru
coronavirus
accord
manufactur
instruct
pcr
mycoplasma
pneumonia
chlamydophila
pneumonia
investig
blood
sputum
endotrach
aspir
urin
sampl
bacteriolog
clinic
indic
initi
urin
sampl
test
pneumococc
legionella
antigen
immunochromatograph
enzym
immunoassay
binax
host
immunolog
respons
monitor
luminex
enzym
immunoassay
luminex
differ
plasma
cytokin
chemokin
statist
analysi
clinic
virolog
immunolog
characterist
compar
fisher
exact
test
x
test
use
categor
variabl
appropri
mannwhitney
u
test
use
continu
variabl
data
normal
distribut
signific
risk
factor
sever
diseas
analyz
multipl
logist
regress
due
small
number
case
linear
regress
use
assess
trend
mean
viral
load
jonckheereterpstra
trend
test
use
compar
cytokin
chemokin
level
clinic
sever
pearson
correl
use
assess
relationship
viral
load
absolut
lymphocyt
count
plasma
cytokin
level
spss
softwar
version
window
spss
use
statist
comput
p
valu
consid
repres
statist
signific
differ
patient
ardsdeath
group
significantli
older
like
obes
underli
diseas
milddiseas
group
tabl
lower
respiratori
tract
symptom
especi
dyspnea
common
present
ardsdeath
group
comparison
patient
ardsdeath
survivedwithoutard
group
reveal
signific
differ
term
demograph
characterist
present
symptom
vital
sign
admiss
except
wheez
common
survivedwithoutard
group
chronic
pulmonari
diseas
common
survivedwithoutard
group
ardsdeath
group
overal
patient
receiv
oseltamivir
nebul
zanamivir
chronic
liver
diseas
epilepsi
thalassemia
trait
hypothyroid
survivedwithoutard
group
comorbid
includ
hypertens
patient
chronic
liver
diseas
chronic
renal
diseas
thalassemia
trait
eczema
e
systol
blood
pressur
mm
hg
diastol
blood
pressur
mm
hg
use
patient
sever
diseas
median
time
initi
oseltamivir
treatment
day
symptom
onset
ardsdeath
group
later
day
survivedwithoutard
group
day
milddiseas
group
three
patient
ardsdeath
group
receiv
oseltamivir
diagnosi
made
death
empir
antibiot
start
patient
ardsdeath
survivedwithoutard
group
admiss
regimen
modifi
accord
bacteriolog
test
result
individu
basi
initi
laboratori
paramet
present
tabl
neutrophil
count
serum
alanin
transaminas
alt
creatin
kinas
lactat
dehydrogenas
level
higher
absolut
lymphocyt
count
lower
ardsdeath
group
milddiseas
group
ardsdeath
group
also
significantli
lower
total
white
blood
cell
neutrophil
platelet
count
alt
level
survivedwithoutard
group
nasopharyng
r
p
p
p
dotrach
viral
load
invers
r
p
p
late
concomit
absolut
lymphocyt
count
initi
nasopharyng
endotrach
viral
load
similar
among
patient
differ
diseas
sever
tabl
peak
viral
load
occur
within
day
symptom
onset
figur
nasopharyng
viral
load
decreas
oseltamivir
therapi
slowest
decreas
ardsdeath
group
figur
viremia
found
rtpcr
patient
ardsdeath
group
patient
survivedwithoutard
group
stool
sampl
patient
survivedwithoutard
group
posit
rtpcr
result
urin
sampl
test
neg
rtpcr
oseltamivir
resist
mutant
exist
quasispeci
differ
specimen
found
patient
survivedwithoutard
group
cytokin
chemokin
assay
significantli
higher
level
granulocyt
colonystimul
factor
gcsf
interferon
ifn
interleukin
il
ifnginduc
protein
monocyt
chemoattract
protein
mcp
tumor
necrosi
factor
tnf
found
initi
sampl
ardsdeath
group
milddiseas
group
tabl
initi
level
lower
ardsdeath
group
milddiseas
group
differ
approach
statist
signific
p
p
compar
survivedwithoutard
group
significantli
higher
level
gcsf
tnfa
found
ardsdeath
group
stratifi
accord
day
symptom
onset
day
day
day
level
higher
sever
diseas
throughout
period
wherea
gcsf
tnfa
level
higher
later
phase
diseas
figur
coinfect
present
occur
ardsdeath
survivedwithoutard
group
tabl
among
ardsdeath
group
communityacquir
methicillinresist
staphylococcu
aureu
cultur
blood
pleural
fluid
sampl
patient
sputum
sampl
anoth
patient
methicillinsuscept
aureu
pseudomona
speci
cultur
patient
respect
one
patient
pulmonari
tuberculosi
sputum
smear
posit
acidfast
bacilli
pcr
posit
mycobacterium
tuberculosi
patient
also
pneumococc
antigenuria
survivedwithoutard
group
haemophilu
influenza
pseudomona
speci
found
patient
rhinoviru
detect
patient
ardsdeath
group
patient
survivedwithoutard
group
respiratori
virus
c
pneumonia
pneumonia
legionella
speci
detect
complic
common
ardsdeath
group
tabl
five
patient
clinic
laboratori
echocardiograph
evid
myocard
case
confirm
postmortem
examin
figur
multiorgan
dysfunct
syndrom
predominantli
occur
ardsdeath
group
one
patient
ardsdeath
group
develop
ventil
associ
pneumonia
enterobact
cloaca
bacteremia
rhabdomyolysi
encephalopathi
found
median
time
death
day
symptom
onset
rang
day
caus
death
respiratori
failur
patient
includ
patient
secondari
bacteri
pneumonia
patient
myocard
heart
failur
due
myocard
patient
escherichia
coli
bacteremia
patient
postmortem
examin
paramortem
tissu
biopsi
perform
patient
die
day
symptom
onset
examin
patient
die
around
day
symptom
onset
show
acut
exud
diffus
alveolar
damag
proteinac
exud
alveolar
space
interstiti
infiltr
alveolar
septa
figur
one
patient
die
day
symptom
onset
fibroprolif
chang
diffus
alveolar
damag
figur
reactiv
hemophagocytosi
found
lymph
node
bone
marrow
patient
figur
lymphoid
atrophi
also
observ
figur
three
case
chang
acut
lymphocyt
myocard
figur
one
case
thrombosi
branch
pulmonari
arteri
figur
splenic
arteri
wedgeshap
infarct
despit
heparin
undergo
extracorpor
membran
oxygen
clinic
studi
sever
pandem
influenza
viru
infect
util
patient
mild
diseas
except
pregnant
patient
laboratori
studi
cell
line
show
viru
similar
recent
season
influenza
viru
term
viral
replic
rate
abil
induc
proinflammatori
cytokin
markedli
inferior
influenza
viru
howev
unlik
season
influenza
viru
replic
mainli
upper
respiratori
tract
challeng
studi
mammal
show
pandem
viru
replic
high
level
upper
lower
respiratori
tract
find
ard
postmortem
find
diffus
alveolar
damag
reactiv
hemophagocytosi
lymphoid
atrophi
deceas
patient
compat
cytokin
storm
similarli
report
infect
therefor
studi
clinic
characterist
serial
viral
load
respiratori
specimen
plasma
level
cytokin
chemokin
group
patient
differ
level
diseas
sever
irrespect
diseas
sever
viral
load
alreadi
peak
within
day
symptom
onset
anim
experi
clinic
studi
show
viral
load
increas
steadili
within
h
inocul
host
fail
mount
innat
immun
respons
innat
immun
respons
mount
viral
load
reach
plateau
due
later
present
sever
case
data
viral
load
initi
day
symptom
onset
scarc
thu
nasopharyng
viral
load
present
appear
slightli
lower
sever
group
later
present
sever
case
might
allow
time
recruit
cytotox
lymphocyt
respons
specif
highli
homolog
nucleoprotein
antigen
present
influenza
virus
suppress
viral
load
slower
declin
viral
shed
observ
sever
patient
ardsdeath
group
survivedwithoutard
group
milddiseas
group
figur
find
could
relat
less
effect
innat
adapt
immun
respons
togeth
delay
start
antivir
therapi
due
later
present
fatal
case
infect
persist
high
viral
load
due
oseltamivir
resist
oseltamivir
resist
respons
slower
rate
declin
viral
shed
seri
patient
infect
oseltamivirresist
viru
eventu
surviv
without
complic
ard
although
uncontrol
viral
infect
unlik
caus
death
ard
antivir
therapi
suppress
viral
load
rapidli
intraven
zanamivir
neutral
antibodi
convalesc
plasma
hyperimmun
intraven
immunoglobulin
consid
random
control
trial
treatment
sever
case
strategi
may
acceler
clearanc
viral
load
may
also
reduc
excess
cytokin
releas
role
proinflammatori
cytokin
chemokin
antivir
activ
damag
host
tissu
highest
level
seen
ardsdeath
group
plasma
cytokin
chemokin
profil
sever
group
consist
challeng
macaqu
model
show
elev
level
inflam
lung
stratifi
time
symptom
onset
signific
correl
diseas
sever
level
throughout
initi
day
symptom
onset
correl
higher
level
sever
influenza
infect
well
establish
anim
human
correl
report
antiinflammatori
cytokin
essenti
dampen
inflammatori
respons
prevent
excess
host
damag
interest
defici
shown
protect
influenza
infect
mice
high
product
elderli
associ
poorer
antibodi
respons
influenza
vaccin
level
report
elev
among
mani
bacteri
viral
infect
despit
regard
proinflammatori
cytokin
recent
anim
model
suggest
high
level
may
actual
decreas
level
antibodi
influenza
contrast
lower
sever
group
consist
previou
studi
show
might
help
protect
lethal
influenza
use
immunomodul
treatment
influenza
still
controversi
appear
effect
antivir
given
concomitantli
seri
lymphopenia
common
among
patient
sever
diseas
seen
sar
coronaviru
infect
furthermor
invers
correl
lymphocyt
count
viral
load
nasopharyng
endotrach
specimen
observ
similar
find
found
patient
infect
lymphopenia
infect
may
due
lymphocyt
apoptosi
mediat
tnfa
also
elev
anoth
possibl
direct
infect
lymphocyt
shown
histopatholog
studi
infect
evid
bacteri
coinfect
present
sever
case
resembl
rate
anoth
autopsi
studi
howev
bacteri
isol
seri
cover
adequ
cours
hospit
nonpulmonari
complic
myocard
might
contribut
mortal
chronic
pulmonari
diseas
exacerb
underli
pulmonari
comorbid
overrepres
survivedwithoutard
group
suggest
although
patient
requir
oxygen
supplement
prognosi
usual
better
respiratori
decompens
due
viral
pneumon
thrombot
phenomena
thrombosi
branch
pulmonari
arteri
splenic
arteri
lead
wedg
splenic
infarct
found
resembl
report
pandem
although
abdomin
symptom
report
import
clinic
manifest
although
vitro
studi
show
viru
could
replic
high
level
intestin
cell
line
gastrointestin
symptom
promin
case
patient
develop
cytokin
storm
shock
requir
inotrop
support
multiorgan
dysfunct
syndrom
frequent
studi
sever
limit
frequent
take
clinic
sampl
prohibit
enrol
children
even
adult
patient
occasion
refus
serial
nasopharyng
blood
sampl
viral
load
affect
minor
differ
sampl
techniqu
problem
affect
group
use
nasopharyng
swab
may
result
lower
viral
load
nasopharyng
aspir
sampl
obtain
swab
chang
clinic
statu
individu
patient
treatment
regimen
could
unifi
may
confound
viral
load
immunolog
profil
summari
slower
control
viral
load
dysregul
cytokin
profil
import
pathogenesi
sever
diseas
new
pandem
viru
preexist
immun
impair
due
underli
diseas
genet
suscept
appar
immunocompet
case
investig
find
mandat
intervent
studi
sever
case
antivir
immunomodulatori
strategi
